Skip to main content

Table 3 Multivariable analyses of risk factors for an impairment caused by reactogenicity or incapacity to work (prime-booster vaccinations)

From: Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers

Variable

OR (95% confidence interval)

P -value

Frequency of an assumed significant impairment caused by reactogenicity

OR represents the odds ratio for a significant impairment after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none)

Based on 6747 vaccine combinations with complete information

 Age (31–40 vs. 18–30)

0.77 (0.66–0.90)

.001

 Age (41–50 vs. 18–30)

0.64 (0.55–0.75)

 < .001

 Age (51–60 vs. 18–30)

0.47 (0.40–0.55)

 < .001

 Age (> 61 vs. 18–30)

0.34 (0.27–0.42)

 < .001

 Male gender

0.73 (0.61–0.87)

 < .001

 Vaccine combination (ChAdOx + ChAdOx vs.  BNT162b2 + BNT162b2)

2.48 (2.08–2.94)

 < .001

Frequency of an assumed significant impairment caused by reactogenicity

OR represents the odds ratio for a significant impairment after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none)

Based on 6747 vaccine combinations with complete information

 Age (31–40 vs. 18–30)

0.77 (0.66–0.90)

.001

 Age (41–50 vs. 18–30)

0.64 (0.55–0.75)

 < .001

 Age (51–60 vs. 18–30)

0.47 (0.40–0.55)

 < .001

 Age (> 61 vs. 18–30)

0.34 (0.27–0.42)

 < .001

 Male gender

0.73 (0.61–0.87)

 < .001

 Vaccine combination (ChAdOx + ChAdOx vs.  BNT162b2 + BNT162b2)

2.48 (2.08–2.94)

 < .001

 Vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx)

1.13 (0.08–1.58)

ns

 Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273)

1.72 (1.25–2.37)

 < .001

 Male gender × vaccine combination

(ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2)

1.28 (0.91–1.80)

ns

 Male gender × vaccine combination

(mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx)

0.75 (0.38–1.49)

ns

 Male gender × vaccine combination

(ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273)

1.06 (0.56–2.01)

ns

Frequency of incapacity to work of one or more days

OR represents the odds ratio for incapacity to after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none)

on 5153 vaccine combinations with complete information

 Age (31–40 vs. 18–30)

0.72 (0.60–0.86)

 < .001

 Age (41–50 vs. 18–30)

0.56 (0.47–0.67)

 < .001

 Age (51–60 vs. 18–30)

0.43 (0.36–0.51)

 < .001

 Age (> 61 vs. 18–30)

0,42 (0.31–0.56)

 < .001

 Male gender

0.73 (0.58–0.92)

.008

 Vaccine combination (mRNA-1273 + mRNA-1273 vs. BNT162b2 + BNT162b2)

1.64 (1.09–2.46)

 < .001

 Vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273)

1.43 ( 0.92–2.23)

ns

 Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx)

1.57 (1.24–1.99)

 < .001

 Male gender × vaccine combination

(mRNA-1273 + mRNA-1273 vs BNT162b2 + BNT162b2)

2.25 (1.00–5.06)

.050

 Male gender × vaccine combination

(ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273)

0.51 (0.21–1.23)

ns

 Male gender × vaccine combination

(ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx)

1.21 (0.76–1.94)

ns

 Vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx)

1.13 (0.08–1.58)

ns

 Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273)

1.72 (1.25–2.37)

 < .001

 Male gender × vaccine combination

(ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2)

1.28 (0.91–1.80)

ns

 Male gender × vaccine combination

(mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx)

0.75 (0.38–1.49)

ns

 Male gender × vaccine combination

(ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273)

1.06 (0.56–2.01)

ns

Frequency of incapacity to work of one or more days

OR represents the odds ratio for incapacity to after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none)

on 5153 vaccine combinations with complete information

 Age (31–40 vs. 18–30)

0.72 (0.60–0.86)

 < .001

 Age (41–50 vs. 18–30)

0.56 (0.47–0.67)

 < .001

 Age (51–60 vs. 18–30)

0.43 (0.36–0.51)

 < .001

 Age (> 61 vs. 18–30)

0,42 (0.31–0.56)

 < .001

 Male gender

0.73 (0.58–0.92)

.008

 Vaccine combination (mRNA-1273 + mRNA-1273 vs. BNT162b2 + BNT162b2)

1.64 (1.09–2.46)

 < .001

 Vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273)

1.43 (0.92–2.23)

ns

 Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx)

1.57 (1.24–1.99)

 < .001

 Male gender × vaccine combination

(mRNA-1273 + mRNA-1273 vs BNT162b2 + BNT162b2)

2.25 (1.00–5.06)

.050

 Male gender × vaccine combination

(ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273)

0.51 (0.21–1.23)

ns

 Male gender × vaccine combination

(ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx)

1.21 (0.76–1.94)

ns